The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Efficacy and safety of modafinil (Provigil(R)) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study
Open accessAbstract
OBJECTIVE: To assess the efficacy and safety of modafinil for the treatment of fatigue in multiple sclerosis (MS). METHODS: Patients aged 18-65 years with a diagnosis of MS, a stable disability level < or =6 on the Kurtzke extended disability status scale (EDSS), and a mean score >4 on the fatigue severity scale (FSS) were eligible for the 9 week, single blind, phase 2, two centre study. Exclusion criteria included a diagnosis of narcolepsy, sleep apnoea, or clinically significant major systemic disease and recent use of medications affecting fatigue. All patients, who remained blinded for the treatment regimen, received placebo during weeks 1-2, 200 mg/day modafinil during weeks 3-4, 400 mg/day modafinil during weeks 5-6, and placebo during weeks 7-9. Safety was evaluated by unblinded investigators. Efficacy was evaluated by self rating scales, using the FSS, the modified fatigue impact scale (MFIS), a visual analogue scale for fatigue (VAS-F), and the Epworth sleepiness scale (ESS). Adverse events were recorded. RESULTS: Seventy two patients (MS type: 74% relapsing-remitting; 7% primary progressive; 19% secondary progressive) received treatment. After treatment with 200 mg/day modafinil for 2 weeks, a significant improvement in fatigue versus placebo run in was demonstrated. Mean scores after treatment with 200 mg/day modafinil were: FSS, 4.7 versus 5.5 for placebo (p<0.001); MFIS, 37.7 versus 44.7 (p<0.001); and VAS-F, 5.4 versus 4.5 (p=0.003). Fatigue scores for 400 mg/day modafinil were not significantly improved versus placebo run in. Mean ESS scores were significantly improved (p<0.001) with 200 mg/day modafinil (7.2) and 400 mg/day (7.0) versus the score at baseline (9.5). Serious adverse events were not found at either dose. The most common adverse events were headache, nausea, and aesthenia. Sixty five patients (90%) completed the study. CONCLUSIONS: These data suggest that 200 mg/day modafinil significantly improves fatigue and is well tolerated in patients with MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Krupp, L. B. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460115022 · Cited by 6,172
Post-Stroke Fatigue: Epidemiology, Clinical Characteristics and Treatment
Acciarresi, M., Bogousslavsky, J., & Paciaroni, M. (2014) · European Neurology · doi:10.1159/000363763 · Cited by 1,417
The impact of fatigue on patients with multiple sclerosis
Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100048691 · Cited by 1,025
Symptomatic fatigue in multiple sclerosis.
Freal, J. E., Kraft, G. H., & Coryell, J. K. (1984) · PubMed · Cited by 526
Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy
Fry, & US Modafinil in Narcolepsy Multicenter Study Group (1998) · Annals of Neurology · doi:10.1002/ana.410430115 · Cited by 396
Vercoulen, J. H. M. M. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550070080014 · Cited by 383
Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy
US Modafinil in Narcolepsy Multicenter Study Group (2000) · Neurology · doi:10.1212/wnl.54.5.1166 · Cited by 362
Krupp, L. B., Coyle, P. K., Doscher, C., Miller, A., Cross, A. H., Jandorf, L., Halper, J., Johnson, B., Morgante, L., & Grimson, R. (1995) · Neurology · doi:10.1212/wnl.45.11.1956 · Cited by 359
Cited by
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Fatigue in neurological disorders
Chaudhuri, A., & Behan, P. O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15794-2 · Cited by 1,297
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin
Morgenthaler, T. I., Kapur, V. K., Brown, T. M., Swick, T. J., Alessi, C., Aurora, R. N., Boehlecke, B., Chesson, A. L., Friedman, L., Maganti, R., et al. (2007) · Sleep · doi:10.1093/sleep/30.12.1705 · Cited by 488
Evidence‐Based Recommendations for the Assessment and Management of Sleep Disorders in Older Persons
Bloom, H. G., Ahmed, I., Alessi, C. A., Ancoli‐Israel, S., Buysse, D. J., Kryger, M. H., Phillips, B. A., Thorpy, M. J., Vitiello, M. V., & Zee, P. C. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02220.x · Cited by 464
Samuels, E., & Szabadi, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777193 · Cited by 454
Fatigue associated with multiple sclerosis: diagnosis, impact and management
Bakshi, R. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms904oa · Cited by 446
Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial
Krupp, L. B., Hyman, L. G., Grimson, R., Coyle, P. K., Melville, P., Ahnn, S., Dattwyler, R., & Chandler, B. (2003) · Neurology · doi:10.1212/01.wnl.0000071227.23769.9e · Cited by 419
Fatigue as a symptom or comorbidity of neurological diseases
Penner, I.-K., & Paul, F. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.117 · Cited by 404
Fatigue in Multiple Sclerosis: Mechanisms, Evaluation, and Treatment
Braley, T. J., & Chervin, R. D. (2010) · Sleep · doi:10.1093/sleep/33.8.1061 · Cited by 403
Origin of Fatigue in Multiple Sclerosis: Review of the Literature
Kos, D., Kerckhofs, E., Nagels, G., D'hooghe, M. B., & Ilsbroukx, S. (2008) · Neurorehabilitation and Neural Repair · doi:10.1177/1545968306298934 · Cited by 397
Felger, J. C., & Miller, A. H. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.09.003 · Cited by 391
Evaluation of the modified fatigue impact scale in four different European countries
Kos, D., Kerckhofs, E., Carrea, I., Verza, R., Ramos, M., & Jansa, J. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1117oa · Cited by 381
Fatigue and cancer: causes, prevalence and treatment approaches
Wagner, L. I., & Cella, D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602012 · Cited by 364
Brown, R. G., Dittner, A., Findley, L., & Wessely, S. C. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.07.007 · Cited by 361
A Systematic Review of Modafinil: Potential Clinical Uses and Mechanisms of Action
Ballon, J. S., & Feifel, D. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0406 · Cited by 349
Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
Stankoff, B., Waubant, E., Confavreux, C., Edan, G., Debouverie, M., Rumbach, L., Moreau, T., Pelletier, J., Lubetzki, C., Clanet, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000158272.27070.6a · Cited by 318
Fatigue in palliative care patients — an EAPC approach
Radbruch, L., Strasser, F., Elsner, F., Gonçalves, J. F., Løge, J., Kaasa, S., Nauck, F., Stone, P., & the Research Steering Committee of the European Association for Palliative Care (EAPC) (2008) · Palliative Medicine · doi:10.1177/0269216307085183 · Cited by 317
de Groot, M. H., Phillips, S. J., & Eskes, G. A. (2003) · Archives of Physical Medicine and Rehabilitation · doi:10.1053/s0003-9993(03)00346-0 · Cited by 260
Psychometric Properties of the Modified Fatigue Impact Scale
Larson, R. D. (2013) · International Journal of MS Care · doi:10.7224/1537-2073.2012-019 · Cited by 258
Friedman, J. H., Alves, G., Hagell, P., Marinus, J., Marsh, L., Martinez‐Martin, P., Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., et al. (2010) · Movement Disorders · doi:10.1002/mds.22989 · Cited by 257
The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders
Dobryakova, E., Genova, H. M., DeLuca, J., & Wylie, G. R. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00052 · Cited by 242
Pharmacological treatments for fatigue associated with palliative care
Mücke, M., Mochamat, M., Cuhls, H., Peuckmann-Post, V., Minton, O., Stone, P., & Radbruch, L. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006788.pub3 · Cited by 227
A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression
DeBattista, C., Lembke, A., Solvason, H. B., Ghebremichael, R., & Poirier, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104910.75206.b9 · Cited by 144
JONES, D. E. J., & NEWTON, J. L. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03223.x · Cited by 114
“that seen in other disease states including narcolepsy (20), HIV infection (21), depression (22) and multiple sclerosis (23,24).”
BackgroundRasch analysis of the Fatigue Severity Scale in multiple sclerosis
Mills, R., Young, C., Nicholas, R., Pallant, J., & Tennant, A. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458508096215 · Cited by 114
A behavioral neuroenergetics theory of ADHD
Killeen, P. R., Russell, V. A., & Sergeant, J. A. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.02.011 · Cited by 97
Amyotrophic lateral sclerosis and palliative care: where we are, and the road ahead
Blackhall, L. J. (2012) · Muscle & Nerve · doi:10.1002/mus.22305 · Cited by 88
Bodenmann, S., Xu, S., Luhmann, U., Arand, M., Berger, W., Jung, H., & Landolt, H. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.222 · Cited by 85
Excessive daytime sleepiness in psychiatry: A relevant focus for clinical attention and treatment?
Hawley, C. J. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600578904 · Cited by 5
Metadata
- Authors
- Rammohan, K. W.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2002-02-01
- Volume
- 72
- Issue
- 2
- Pages
- 179-183
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2037902784
- Cited by
- 442
- References
- 19
- FWCI
- 21.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.